Tumour therapy with radionuclides: Assessment of progress and problems

Radiotherapy and Oncology

Volumn 66, Issue 2, 2003, Pages 107-117

  Carlsson, Jörgen ^a   Aronsson, Eva Forssell ^b   Hietala, Sven Ola ^c   Stigbrand, Torgny ^c   Tennvall, Jan ^d  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Disseminated tumour cells; Low dose rate; Metastasis; Radiation effects; Radionuclide therapy; Review; Tumour therapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 125; (3 IODOBENZYL)GUANIDINE I 131; ANTIBODY; ASTATINE 211; BISMUTH; BISMUTH 213; CHLORIDE SR 89; COPPER 67; GEFITINIB; INDIUM 111; IODINE 125; IODINE 131; LEXIDRONAM SAMARIUM SM 153; LUTETIUM; PHOSPHATE P 32; RADIOISOTOPE; RHENIUM 186; RHENIUM 188; RHODIUM; SOMATOSTATIN; UNCLASSIFIED DRUG; YTTRIUM 90;

BINDING AFFINITY; BONE METASTASIS; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CELL LEVEL; CELL NUCLEUS; CELL TRANSPORT; CELLULAR DISTRIBUTION; DISSEMINATED CANCER; DOSIMETRY; DRUG DEGRADATION; DRUG DESIGN; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG PENETRATION; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG UPTAKE; ENDOCRINE TUMOR; GENETIC STABILITY; HEMATOLOGIC DISEASE; HEMATOPOIESIS; IMMUNE RESPONSE; INTERNALIZATION; ISOTOPE LABELING; LEUKEMIA; METASTASIS; MOLECULAR WEIGHT; NEUROBLASTOMA; PHEOCHROMOCYTOMA; POLYCYTHEMIA; PRIORITY JOURNAL; RADIATION DOSE; RADIOBIOLOGY; RADIOISOTOPE THERAPY; REVIEW; SOLID TUMOR; SYSTEMIC CIRCULATION; THROMBOCYTHEMIA; THYROID CANCER; TREATMENT PLANNING; TUMOR CELL;

EID: 0037295293     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(02)00374-2     Document Type: Review

References (120)

1. Ahmed N.U., Ueda M., Ichihashi M. Increased level of c-erbB-2/neu/HER-2 protein in cutaneous squamous cell carcinoma. Br J Dermatol. 136:1997;908-912.
2. Adams G.P., Schier R. Generating improved single-chain Fv molecules for tumor targeting. J Immunol Methods. 231:1999;249-260.
3. Adams G.P., Schier R., McCall A.M., et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 61:2001;4750-4755.
4. Akabani G., Cokgor I., Coleman R.E., et al. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int J Radiat Oncol Biol Phys. 46:2000;947-958.
5. Anderson P.M., Wiseman G.A., Dispenzieri A., et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 20:2002;189-196.
6. Barendswaard E.C., Humm J.L., O'Donoghue J.A., et al. Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft. J Nucl Med. 42:2001;1251-1256.
7. Barton J., Blackledge G., Wakeling A. Growth factors and their receptors: new targets for prostate cancer therapy. Urology. 58:2001;114-122.
8. Behe M., Du J., Becker W., et al. Biodistribution, blood half-life, and receptor binding of a somatostatin-dextran conjugate. Med Oncol. 18:2001;59-64.
9. Behr T.M., Becker W.S., Sharkey R.M., et al. Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion. J Nucl Med. 37:1996;829-833.
10. Behr T.M., Goldenberg D.M., Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med. 25:1998;201-212.
11. Behr T.M., Sgouros G., Stabin M.G., et al. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters. Clin Cancer Res. 5:1999;3031s-3043s.
12. Behr T.M., Blumenthal R.D., Memtsoudis S., et al. Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments. Clin Cancer Res. 6:2000;4900-4907.
13. Behr T.M., Gotthardt M., Barth A., Behe M. Imaging tumors with peptide-based radioligands. Q J Nucl Med. 45:2001;189-200.
14. Behr T.M., Liersch T., Greiner-Bechert L., et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer. 94:2002;1373-1381.
15. Bernhardt P., Forssell-Aronsson E., Jacobsson L., Skarnemark G. Low-energy electron emitters for targeted radiotherapy of small tumours. Acta Oncol. 40:2001;602-608.
16. Bertram J.S. The molecular biology of cancer. Mol Aspects Med. 21:2000;167-223.
17. Boerman O.C., Oyen W.J., Corstens F.H. Radio-labeled receptor-binding peptides: a new class of radiopharmaceuticals. Semin Nucl Med. 30:2000;195-208.
18. Bohl Kullberg E., Bergstrand N., Carlsson J., et al. Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents. Bioconjug Chem. 13:(4):2002;737-743.
19. Buchsbaum D.J. Experimental radioimmunotherapy. Semin Radiat Oncol. 10:2000;156-167.
20. Bue P., Holmberg A.R., Marquez M., Westlin J.E., Nilsson S., Malmstrom P.U. Intravesical administration of EGF-dextran conjugates in patients with superficial bladder cancer. Eur Urol. 38:2000;584-589.
21. Carlsson J., Blomquist E., Gedda L., et al. Conjugate chemistry and cellular processing of EGF-dextran. Acta Oncol. 38:1999;313-321.
22. Casalini P., Luison E., Menard S., Colnaghi M.I., Paganelli G., Canevari S. Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization. J Nucl Med. 38:1997;1378-1381.
23. Colnot D.R., Quak J.J., Roos J.C., et al. Radioimmunotherapy in patients with head and neck squamous cell carcinoma: initial experience. Head Neck. 23:2001;559-565.
24. deHerder W.W., Lamberts S.W. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr Opin Oncol. 14:2002;53-57.
25. 3]octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer. 92:2001;628-633.
26. DeNardo G.L., O'Donnell R.T., Kroger L.A., et al. Strategies for developing effective radioimmunotherapy for solid tumors. Clin Cancer Res. 5:1999;3219s-3223s.
27. Emfietzoglou D., Kostarelos K., Sgouros G. An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy. J Nucl Med. 42:2001;499-504.
28. 131I-labelled E4 antibodies on cells at different depth in DU 145 spheroids. Int J Cancer. 63:1995;387-394.
29. 111In-DTPA-Phe-1-octreotide. J Nucl Med. 36:1995;7-12.
30. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med. 41:2000;636-642.
31. Foulon C.F., Reist C.J., Bigner D.D., Zalutsky M.R. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody. Cancer Res. 60:2000;4453-4460.
32. Frantz G.D., Pham T.Q., Peale F.V. Jr, Hillan K.J. Detection of novel gene expression in paraffin-embedded tissues by isotopic in situ hybridization in tissue microarrays. J Pathol. 195:2001;87-96.
33. 125I-ChBR96-biotin monoclonal antibody using whole blood immunoadsorption (WBIA). J Nucl Med. 38:1997;895-901.
34. 111In Labeled MAb BR96 for tumor targeting in combination with extracorporeal immunoadsorption. Clin Cancer Res. 5:1999;3059-3064.
35. 188Re-labeled bivalent hapten: biodistribution and dosimetry studies. J Nucl Med. 42:2001;146-153.
36. Giammarile F., Mognetti T., Resche I. Bone pain palliation with strontium-89 in cancer patients with bone metastases. Q J Nucl Med. 45:2001;78-83.
37. Goldenberg D.M. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol. 39:(1-2):2001;195-201.
38. Goldenberg D.M. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 43:(5):2002;693-713.
39. Govindan S.V., Mattes M.J., Stein R., et al. Labeling of monoclonal antibodies with diethylenetriaminepentaacetic acid-appended radioiodinated peptides containing D-amino acids. Bioconjugate Chem. 10:1999;231-240.
40. Hall E.J. Time, dose and fractionation in radiotherapy. Hall E.J. Radiobiology for the radiologist. 5th ed. 2000;397-418 Williams & Wilkins, Philadelphia, PA. (Chapter 22).
41. Hainsworth J.D. Monoclonal antibody therapy in lymphoid malignancies. Oncologist. 5:2000;376-384.
42. Harris J.M., Martin N.E., Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet. 40:2001;539-551.
43. Hartman T., Lundqvist H., Westlin J.E., Carlsson J. Radiation doses to the cell nucleus in single cells and cells in micrometastases in targeted therapy with (131)I labeled ligands or antibodies. Int J Radiat Oncol Biol Phys. 46:2000;1025-1036.
44. Heppeler A., Froidevaux S., Eberle A.N., Maecke H.R. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem. 7:2000;971-994.
45. Hindorf C., Linden O., Tennvall J., Wingårdh K., Strand S.E. Time dependence of the activity concentration ratio of red marrow to blood and implications for red marrow dosimetry. Cancer. 94:2002;1235-1239.
46. Hoefnagel C.A. Radionuclide cancer therapy. Ann Nucl Med. 12:1998;61-70.
47. Hoefnagel C.A. Nuclear medicine therapy of neuroblastoma. Q J Nucl Med. 43:1999;336-343.
48. Hofer K.G. Biophysical aspects of Auger processes. Acta Oncol. 39:2000;651-658.
49. Hoos A., Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest. 81:2001;1331-1338.
50. Imam S.K. Status of radioimmunotherapy in the new millennium. Cancer Biother Radiopharm. 16:2001;237-256.
51. Jager D., Jager E., Knuth A. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol. 54:2001;669-674.
52. Jain R.K. Haemodynamic and transport barriers to the treatment of solid tumours. Int J Radiat Biol. 60:1991;85-100.
53. 111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors. J Nucl Med. 41:2000;1514-1518.
54. Jenkins R.E., Pennington S.R. Arrays for protein expression profiling: towards a viable alternative to two-dimensional gel electrophoresis? Proteomics. 1:2001;13-29.
55. Johansson A., Eriksson D., Ullen A., et al. The combination of external beam radiotherapy and experimental radioimmunotargeting with a monoclonal anticytokeratin antibody. Cancer. 94:2002;1314-1319.
56. Johnson T.A., Press O.W. Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience. Ann Hematol. 79:2000;175-182.
57. Joiner M.C., Marples B., Lambin P., Short S.C., Turesson I. Low-dose hypersensitivity: current status and possible mechanisms. Int J Radiat Oncol Biol Phys. 49:2001;379-389.
58. Jurcic J.G. Antibody therapy of acute myelogenous leukemia. Cancer Biother Radiopharm. 15:2000;319-326.
59. Kairemo K.J., Tenhunen M., Jekunen A.P. Gene therapy using antisense oligodeoxynucleotides labeled with Auger-emitting radionuclides. Cancer Gene Ther. 5:1998;408-412.
60. Kaminski M., Zelenetz A., Press O., et al. Pivotal study of iodine I-131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 19:2001;3918-3928.
61. Kashmiri S.V., Iwahashi M., Tamura M., Padlan E.A., Milenic D.E., Schlom J. Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49. Crit Rev Oncol Hematol. 38:(1):2001;3-16.
62. Kwekkeboom D., Krenning E.P., de Jong M. Peptide receptor imaging and therapy. J Nucl Med. 41:2000;1704-1713.
63. 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. J Nucl Med. 40:1999;1197-1203.
64. Lee L.S., Conover C., Shi C., Whitlow M., Filpula D. Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds. Bioconjug Chem. 10:1999;973-981.
65. Lichtner R.B., Menrad A., Sommer A., Klar U., Schneider M.R. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res. 61:2001;5790-5795.
66. 131I-labeled Anti-CD22 Mab (LL2) in patients with previously treated B-cell lymphomas. Clin Cancer Res. 5:1999;3287s-3291s.
67. Linden O., Hindorf C., Tennvall J., Segren S., Wingardh K., Strand S.E. Single tumor cell uptake and dosimetry of technetium-99m Fab' or minute anti-CD22 in low-grade B-cell lymphoma. Cancer. 94:2002;1270-1274.
68. Lundqvist H., Lubberink M., Tolmachev V., et al. Positron emission tomography and radioimmunotargeting - general aspects. Acta Oncol. 38:1999;335-341.
69. Macklis R.M., Beresford B.A., Palayoor S., Sweeney S., Humm J.L. Cell cycle alterations, apoptosis, and response to low-dose-rate radioimmunotherapy in lymphoma cells. Int J Radiat Oncol Biol Phys. 27:1993;643-650.
70. Maisano R., Pergolizzi S., Cascinu S. Novel therapeutic approaches to cancer patients with bone metastasis. Crit Rev Oncol Hematol. 40:2001;239-250.
71. Mattes M.J., Shih L.B., Govindan S.V., et al. The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody. Int J Cancer. 71:1997;429-435.
72. Maughan N.J., Lewis F.A., Smith V. An introduction to arrays. J Pathol. 195:2001;3-6.
73. Maynard J., Georgiou G. Antibody engineering. Annu Rev Biomed Eng. 2:2000;339-376.
74. McDevitt M.R., Dangshe M., Lai L.T., et al. Tumor therapy with targeted atomic nanogenerators. Science. 294:2001;1537-1541.
75. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 27:(19):2000;6550-6565.
76. Mirzaie-Joniani H., Eriksson D., Sheikholvaezin A., et al. Apoptosis induced by low-dose and low-dose-rate radiation. Cancer. 94:2002;1210-1214.
77. Mitchell C.R., Folkard M., Joiner M.C. Effects of exposure to low-dose-rate (60)co gamma rays on human tumor cells in vitro. Radiat Res. 158:(3):2002;311-318.
78. Molina M.A., Saez R., Ramsey E.E., et al. NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res. 8:2002;347-353.
79. Mothersill C., Seymour C. Radiation-induced bystander effects: past history and future directions. Radiat Res. 155:2001;759-767.
80. Niehans G.A., Singleton T.P., Dykoski D., Kiang D.T. Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst. 85:1993;1230-1235.
81. Nilsson P., Gedda L., Sjöström A., Carlsson J. Penetration and binding of EGF-dextran conjugates in cultured cell spheroids. Tumor Biol. 22:2001;229-238.
82. O'Donoghue J.A. Dosimetric aspects of radioimmunotherapy. Tumor Targeting. 3:1998;105-111.
83. O'Donoghue J.A., Wheldon T.E. Targeted radiotherapy using Auger electron emitters. Phys Med Biol. 41:1996;1973-1992.
84. O'Donoghue J.A., Bardies M., Wheldon T.E. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 36:1995;1902-1909.
85. Onyango P. Genomics and cancer. Curr Opin Oncol. 14:2002;79-85.
86. Orlandi F., Caraci P., Mussa A., Saggiorato E., Pancani G., Angeli A. Treatment of medullary thyroid carcinoma: an update. Endocr Relat Cancer. 8:2001;135-147.
87. Paganelli G., Grana C., Chinol M., et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med. 26:1999;348-357.
88. Palm S., Back T., Claesson I., et al. Effects of the alpha-particle emitter At-211 and low-dose-rate gamma-radiation on the human cell line Colo-205 as studied with a growth assay. Anticancer Res. 18:1998;1671-1676.
89. Pietras K., Ostman A., Sjoquist M., et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 61:2001;2929-2934.
90. Press O.W., Eary J., Appelbaum F., et al. Phase II trial of I-131-B1 (anti-CD20) antibody therapy with autologous stem cell transplantantion for relapsed B cell lymphomas. Lancet. 346:1995;336-340.
91. Press O.W., Shan D., Howell-Clark J., et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 56:1996;2123-2129.
92. Prise K.M., Belyakov O.V., Newman H.C., et al. Non-targeted effects of radiation: bystander responses in cell and tissue models. Radiat Prot Dosimetry. 99:(1-4):2002;223-226.
93. Reist C.J., Archer G.E., Kurpad S.N., et al. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res. 55:1995;4375-4382.
94. Reist C.J., Garg P.K., Alston K.L., Bigner D.D., Zalutsky M.R. Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res. 56:1996;4970-4977.
95. Rossi Norrlund R., Ullen A., Sandstrom P., et al. Experimental radioimmunotargeting combining nonlabeled, iodine-125-labeled, and anti-idiotypic anticytokeratin monoclonal antibodies: a dosimetric evaluation. Cancer. 80:1997;2689-2698.
96. Sandstrom P., Johansson A., Ullen A., et al. Idiotypic-anti-idiotypic antibody interactions in experimental radioimmunotargeting. Clin Cancer Res. 5:1999;3073s-3078s.
97. Savelyeva L., Schwab M. Amplification of oncogenes revisited: from expression profiling to clinical application. Cancer Lett. 167:2001;115-123.
98. Serafini A.N. Therapy of metastatic bone pain. J Nucl Med. 42:2001;895-906.
99. Shih L.B., Thorpe S.R., Griffiths G.L., et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med. 35:1994;899-908.
100. Stigbrand T., Ullen A., Sandstrom P., et al. Twenty years with monoclonal antibodies: state of the art - where do we go? Acta Oncol. 35:1996;259-265.
101. 90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med. 25:1998;668-674.
102. Strand S.E., Ljungberg M., Tennvall J., Norrgren K., Garkavij M. Radio-immunotherapy dosimetry with special emphasis on SPECT quantification and extracorporeal immuno-adsorption. Med Biol Eng Comput. 32:1994;551-561.
103. Tennvall J., Garkavij M., Chen J.Q., Sjögren H.O., Strand S.E. Improving tumor-to-normal-tissue ratios of antibodies by extracorporeal immunoadsorption based on the avidin-biotin concept. Cancer. 80:1997;2411-2418.
104. Tennvall J., Abrahamsson P.A., Ahlgren G., et al. Palliative radiation with a radiolabeled diphosphonate (rhenium-186 etidronate) in patients with hormone-refractory disseminated prostate carcinoma. Scand J Urol Nephrol. 34:2000;188-193.
105. Tewari K.S., Kyshtoobayeva A.S., Mehta R.S., et al. Biomarker conservation in primary and metastatic epithelial ovarian cancer. Gynecol Oncol. 78:2000;130-136.
106. 114mIn, a candidate for radionuclide therapy: low-energy cyclotron production and labeling of DTPA-D-phe-octreotide. Nucl Med Biol. 27:2000;183-188.
107. Ugur O., Kothari P.J., Finn R.D., et al. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol. 29:2002;147-157.
108. Wang Z., Garkavij M., Tennvall J.G., Ohlsson T., Strand S.E., Sjögren H.O. Application of extracorporeal immunoadsorption to reduce circulating blood radioactivity after intraperitoneal administration of indium-111-HMFG1-biotin. Cancer. 94:2002;1287-1292.
109. Veronese F.M. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials. 22:2001;405-417.
110. White C.A., Weaver R.L., Grillo-Lopez A.J. Antibody-targeted immunotherapy for treatment of malignancy. Annu Rev Med. 52:2001;125-145.
111. Wikstrand C.J., Cokgor I., Sampson J.H., Bigner D.D. Monoclonal antibody therapy of human gliomas: current status and future approaches. Cancer Metastasis Rev. 18:1999;451-464.
112. Wilbur D.S., Pathare P.M., Hamlin D.K., et al. Development of new biotin/streptavidin reagents for pretargeting. Biomol Eng. 16:(1-4):1999;113-118.
113. Virgolini I., Traub T., Novotny C., et al. New trends in peptide receptor radioligands. Q J Nucl Med. 45:2001;153-159.
114. Wiseman G., White C., Sparks R., et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin® radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol. 39:2001;181-194.
115. 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res. 6:2000;3855-3863.
116. Wu A.M. Tools for pretargeted radioimmunotherapy. Cancer Biother Radiopharm. 16:2001;103-108.
117. Yao Z., Garmestani K., Wong K.J., et al. Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. J Nucl Med. 42:2001;1538-1544.
118. 125I-estrogen decays in estrogen receptor-expressing MCF-7 human breast cancer cells. Radiat Res. 155:2001;328-334.
119. Zalutsky M.R., Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Des. 6:2000;1433-1455.
120. Zweit J. Radionuclides and carrier molecules for therapy. Phys Med Biol. 41:(10):1996;1905-1914.